Stay updated with breaking news from Pd L1 Expression. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Professionals deliberate the progression of Immuno-Oncology combinations while also engaging in conversations regarding the issue of immunotherapy resistance.
Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.
Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.
Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.
The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.